Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
29.11.2024 11:30:00 CET | news aktuell GmbH | Press release
- Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
- Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board

Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.
Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.
The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.
Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”
Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.
For further information, please visit: www.fair-med.com/newsroom
Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690
Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.
Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.
Images

Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
HEIDELBERG forges ahead with transformation – foundations laid for medium-term growth10.6.2026 08:57:51 CEST | Press release
Dual-use technology approach on target – establishing new areas of business based on core expertise boosts strategic diversification Strong partnerships – new Memorandum of Understanding to be announced at ILA between ONBERG and Ukrainian company Core business stable – global positioning ensures robust development and underlines market leadership Focus on efficiency – cost base streamlined and competitiveness strengthened Financial year 2025/2026 – EBITDA margin down on previous year, while sales and net result after taxes improve Outlook for financial year 2026/2027 – challenging geopolitical environment, systematic expansion of HEIDELBERG Technology growth segment
The Virchow Prize 2026 Awarded for Pioneering Work on Ebola, Advancing Global Epidemic Preparedness and Fostering Global Solidarity3.6.2026 12:37:54 CEST | Press release
Jean-Jacques Muyembe and Peter Piot are being honored with the international award of €500,000 for exceptional life-long leadership spanning five decades since the first outbreak of Ebola
Hidden AI agents could become the new gatekeepers of commerce, warns new Fintech 2040 paper3.6.2026 12:25:33 CEST | Press release
A new Fintech 2040 paper from Professor Roland Frank explores how AI agents are moving from passive assistants to autonomous actors capable of searching, selecting and purchasing products on behalf of consumers — fundamentally reshaping the future of ecommerce and payments.
OSD supplies Principality of Andorra with EU Standard Driving Licence and Advanced Personalisation System3.6.2026 09:00:00 CEST | Press release
Andorra/Vienna – The Austrian State Printing Company (OSD) is proud to supply the Principality of Andorra with a new EU‑standardized driving licence card and a fully integrated state‑of‑the‑art personalisation platform by OSD. The solution, delivered to the Andorran Departament de Seguretat Industrial i Vehicles (Ministeri de Presidència, Economia, Treball i Habitatge), went live in the end of 2025 and sets a new benchmark for security, usability and European compliance.
Westfalia-Automotive achieves debt forgiveness and release from all First Brands Group related claims1.6.2026 15:57:14 CEST | Press release
Rheda-Wiedenbrück, Germany – After successfully separating from First Brands Group in March 2026, Westfalia Automotive Group has completed a transaction resulting in debt forgiveness for group entities in the amount of approximately USD 246 million, as well as a release from all First Brands related claims.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom